Relmada Jumps as Jefferies Upgrades on a Potential Turnaround Story
Relmada Therapeutics Analyst Ratings
Alkermes Analyst Ratings
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
ADVISORSHARES PSYCHEDELICS ETF To Carry Out 1-for-10 Reverse Stock Split On September 10th, 2024
AdvisorShares Announces 1-For-10 Reverse Split Of ETF, Effective September 10, 2024
ATAI Life Sciences Analyst Ratings
Mind Medicine Analyst Ratings
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript Summary
Atai Life Sciences Psychedelic Drug for Depression Demonstrates Safety in Phase 1
Here's the Major Earnings After the Close Today
Here Is the Next Potential Market Catalyst
VistaGen Therapeutics Q1 2025 Earnings Preview
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Medical Journal Retracts Three Articles Related to MDMA for PTSD